Vericel (VCEL) Enterprise Value (2010 - 2026)
Vericel (VCEL) posted Enterprise Value of -$162.5 million for Q2 2026, down 11.8% sequentially from -$145.3 million in Q1 2026, and down 39.03% YoY from -$266.5 million in Q2 2025.
Analysis
Vericel (VCEL) Enterprise Value (2010 - 2026) Analysis & Trends
Vericel has reported Enterprise Value for 15 years, with the latest figure at -$162.5 million in Q2 2026.
- Quarterly Enterprise Value fell 39.03% year-over-year to -$162.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$162.5 million (down 39.03% YoY) and the FY2025 annual result came in at -$137.5 million, down 18.32% from the prior year.
- Enterprise Value declined to -$162.5 million in Q2 2026 per VCEL's latest filing, from -$145.3 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$97.8 million in Q2 2023 and troughed at -$162.5 million in Q2 2026.
- A 5-year average of -$117.0 million and a median of -$111.9 million in 2022 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2023 and 2026: Enterprise Value gained 8.35% in 2023, then slumped 39.03% in 2026.
- Over 5 years, Enterprise Value stood at -$119.5 million in 2022, then grew by 8.35% to -$109.6 million in 2023, then fell by 6.08% to -$116.2 million in 2024, then fell by 18.32% to -$137.5 million in 2025, then retreated by 18.18% to -$162.5 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$162.5 million, -$145.3 million, and -$137.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.11 Bn |
| Mar 31, 2026 | 1.50 Bn |
| Dec 31, 2025 | 1.69 Bn |
| Sep 30, 2025 | 1.46 Bn |
| Jun 30, 2025 | 2.03 Bn |
| Mar 31, 2025 | 2.13 Bn |
| Dec 31, 2024 | 2.61 Bn |
| Sep 30, 2024 | 1.98 Bn |
| Jun 30, 2024 | 2.14 Bn |
| Mar 31, 2024 | 2.41 Bn |
| Dec 31, 2023 | 1.59 Bn |
| Sep 30, 2023 | 1.49 Bn |
| Jun 30, 2023 | 1.69 Bn |
| Mar 31, 2023 | 1.27 Bn |
| Dec 31, 2022 | 1.13 Bn |
| Sep 30, 2022 | 984.12 Mn |
| Jun 30, 2022 | 1.09 Bn |
| Mar 31, 2022 | 1.70 Bn |
| Dec 31, 2021 | 1.74 Bn |
| Sep 30, 2021 | 2.18 Bn |